Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risk stratification in chronic lymphocytic leukemia.

Till Seiler1, Hartmut Döhner, Stephan Stilgenbauer

  • 1Department of Internal Medicine III, University of Ulm, Ulm, Germany.

Seminars in Oncology
|April 18, 2006
PubMed
Summary

New molecular markers like genomic aberrations and serum proteins can predict chronic lymphocytic leukemia (CLL) progression. These findings aid in risk stratification for personalized CLL treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APL-like subset within <i>NPM1</i>-mutated AML: A distinct immunophenotype correlating with early vascular complications.

HemaSphere·2026
Same author

Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies.

Bone marrow transplantation·2026
Same author

Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia.

Leukemia·2026
Same author

Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study.

Leukemia·2026
Same author

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Blood·2026
Same author

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AML.

Future oncology (London, England)·2025

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic lymphocytic leukemia (CLL) exhibits highly variable clinical outcomes.
  • Current treatments for CLL can induce remission but do not prevent eventual relapse.

Purpose of the Study:

  • To identify and evaluate molecular and cellular markers for predicting disease progression in CLL patients.
  • To assess the prognostic value of these markers independent of clinical factors.

Main Methods:

  • Analysis of genomic aberrations.
  • Assessment of IgVH gene mutational profile and ZAP-70 expression.
  • Measurement of serum B2-microglobulin (beta2-MG) and thymidine kinase (TK) levels.

Main Results:

Related Experiment Videos

  • Identified genomic aberrations, IgVH mutational status, ZAP-70 expression, beta2-MG, and TK as significant prognostic indicators in CLL.
  • These molecular markers provide prognostic information independently of established clinical characteristics.

    • Conclusions:

    • Molecular markers are emerging as crucial tools for risk stratification in CLL.
    • These markers hold promise for tailoring treatment strategies and improving patient outcomes in clinical trials.